Clinical trials: Gastric (Stomach) Cancer
Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas
68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates.
- Conditions
- Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas, Gep Net
- Trial name
- RGS-GEP-NET (NCT05448157)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
Stomach Neoplasm, Robotic Surgery
Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer
The purpose of this study is to explore the clinical outcomes of the robotic distal gastrectomy for patients with gastric adenocarcinoma（cT1-4a, N-/+, M0）.
- Trial name
- RDG (NCT03313700)
- Testing
- Robotic Distal Gastrectomy, Laparoscopic Distal Gastrectomy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fujian Medical University
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Lynch Syndrome, FAP
Hereditary Colorectal and Associated Tumor Registry Study
After informed consent, participants will be asked to complete a medical/family history questionnaire and provide a blood sample.
- Conditions
- Lynch Syndrome, FAP, Hereditary Diffuse Gastric Cancer, Juvenile Polyposis Syndrome
- Trial name
- NCT00633607
- Testing
- Research Registry
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- University of Pittsburgh
Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma
Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer
GastroPET is a prospective, multicenter, non-randomized interventional study evaluating sequential FDG-PET as an early biomarker to guide preoperative treatment in patients with locally advanced resectable oesophago-gastric…
- Conditions
- Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- GastroPET (NCT07791329)
- Testing
- FDG-PET
- Where
- Czechia
- Volunteers
- 144 people
- Sponsor
- Masaryk Memorial Cancer Institute
Gastric Cancer Stage IIIB-IIIC
Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
it is an an Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination with SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer
- Trial name
- NCT06036745
- Testing
- Pembrolizumab + SOX
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Gastric Cancer
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of advanced gastric cancer after first-line resistance
- Trial name
- NCT05751265
- Testing
- Tislelizumab, 5Fu, Paclitaxel injection
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer
Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer
In China, S-1 is an novel oral fluoropyrimidine with demonstrated high efficacy on gastrointestinal cancer. The new regimen with oxaliplatin and leucovorin is expected to achieve more encouraging efficacy on gastric cancer.
- Trial name
- NCT01980407
- Testing
- S-1, leucovorin, oxaliplatin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Jilin Provincial Tumor Hospital
Gastric Cancer (Diagnosis), Gastric Cancer Patient
Peri-habilitation for Patients With Gastric Cancer
This study aims to evaluate the clinical applicability of a peri-habilitation program in patients with gastric cancer by applying nutritional intervention for approximately two weeks before surgery and a combined exercise and…
- Conditions
- Gastric Cancer (Diagnosis), Gastric Cancer Patient, Gastric Cancer Patients Undergoing Gastrectomy, Gastric Cancer Patients Undergoing Minimally Invasive Gastrectomy
- Trial name
- NCT07201857
- Testing
- nutrition education plus active supplement, Exercise
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Korea University Anam Hospital
Early Gastric Cancer
Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2)
Laparoscopic sentinel lymph node dissection and stomach preserving surgery in early gastric cancer is less invasive method which can increase quality of life.
- Trial name
- NCT03837301
- Testing
- NESS-EFTR with sentinel lymph node navigation
- Where
- South Korea
- Volunteers
- 88 people
- Sponsor
- National Cancer Center, Korea
Gastric Cancer
Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)
Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.
- Trial name
- NCT02596256
- Testing
- Apatinib, Docetaxel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
This single-center, dual-cohort, exploratory phase II trial evaluates the efficacy and safety of trastuzumab rezetecan (SHR-A1811), an anti-HER2 antibody-drug conjugate (ADC), with or without the anti-PD-L1 antibody adebrelimab…
- Trial name
- NCT07912957
- Testing
- Trastuzumab Rezetecan (SHR-A1811), Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fudan University
Chronic Myeloid Leukemia, Chronic Phase
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and fasting meals separately（Selection of high-fat…
- Trial name
- CML (NCT03882281)
- Testing
- HQP1351
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Ascentage Pharma Group Inc.
Gastric Cancer
mFLOT Chemotherapy as First-line Treatment in GC
A single center phase 1b/2 trail to identified suitable dosage and its efficacy of modified FLOT regime in Chinese gastric cancer patients.
- Trial name
- NCT03606928
- Testing
- docetaxel, oxaliplatin, 5-FU, leucovorin
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Stomach Neoplasms, Rectal Neoplasms
Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa on the reduction in red blood cell transfusions needed in gastric cancer patients and rectal cancer patients undergoing a treatment plan of…
- Trial name
- NCT00036400
- Testing
- epoetin alfa
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Gastric Cancer
Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
The purpose of this study is to determine whether S-1 and oxaliplatin as neoadjuvant chemotherapy may improve survival benefit compared with control.
- Trial name
- NCT01090505
- Testing
- Drug: S-1 and oxaliplatin
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chinese PLA General Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or…
- Trial name
- NCT02514551
- Testing
- Ramucirumab, Paclitaxel
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
Gastroenteropancreatic Neuroendocrine Tumor, Radiotherapy
Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
Operandi project aims to address unmet clinical needs in the current management of GEP-NETs treated with PRRT by exploring new opportunities provided by imaging-based (AI algorithms) and data augmentation, simultaneous…
- Trial name
- OPERANDI-NET (NCT06256705)
- Testing
- Simultaneous 68Ga-DOTATOC PET-MRI
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer
- Trial name
- NCT05514717
- Testing
- XMT-2056
- Where
- 14 sites in United States
- Volunteers
- 57 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.